Literature DB >> 14656914

No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion.

Thorsten Reffelmann1, Sharon L Hale, Joan S Dow, Robert A Kloner.   

Abstract

BACKGROUND: No-reflow after reperfusion therapy for myocardial infarction is a strong predictor of clinical outcome. But its fate on a long-term basis and potential significance for infarct healing are not yet known. METHODS AND
RESULTS: Twenty-nine female Fisher rats were subjected to 60 minutes of coronary occlusion followed by reperfusion. At 4 weeks, 15 survivors were euthanized after measurement of regional myocardial blood flow (radioactive microspheres) and in vivo staining of perfused tissue (0.5 mL 50% Uniperse blue IV). Infarct size (34.3+/-3.4%), scar thickness (1.19+/-0.10 mm), and infarct expansion index (0.51+/-0.04) were assessed from histological sections (2 additional exclusions because of failed occlusion). Regional myocardial blood flow in the reperfused infarct was reduced significantly compared with noninfarcted tissue (1.98+/-0.47 versus 4.55+/-0.86 mL x min(-1) x g(-1), P<0.003, apical slice, and 1.77+/-0.44 versus 5.34+/-0.38 mL x min(-1) x g(-1), P<0.0001, second slice), accompanied by a striking reduction of perfused capillaries within the infarct (n=23+/-4 versus 163+/-8 in the noninfarcted tissue, P<0.0001, microscopically assessed as capillaries containing blue particles per high-power field). Macroscopically, no-reflow areas were visible in 9 of 13 hearts. The number of perfused capillaries within the infarct correlated significantly with infarct expansion index (r=-0.76, P<0.003), infarct thickness (r=0.60, P<0.03), and the ratio of infarct to septum thickness (r=0.74, P<0.004).
CONCLUSIONS: The no-reflow phenomenon persists for 1 month after reperfusion and predicts worse scar thinning and infarct expansion. Thus, one might shift the "open-artery" hypothesis downstream to an "open-microvessel" hypothesis, relating infarct healing, infarct expansion, and outcome to the completeness of microvascular reperfusion above and beyond epicardial artery patency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656914     DOI: 10.1161/01.CIR.0000101917.80668.E1

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Relationship between retrograde coronary blood flow and the extent of no-reflow and infarct size in a porcine ischemia-reperfusion model.

Authors:  Stavros Stavrakis; John Terrovitis; Elias Tsolakis; Stavros Drakos; Argirios Dalianis; Michael Bonios; Dimitrios Koudoumas; Konstantinos Malliaras; John Nanas
Journal:  J Cardiovasc Transl Res       Date:  2010-12-09       Impact factor: 4.132

Review 2.  Current status of cardiac MRI in small animals.

Authors:  J-P Vallée; M K Ivancevic; D Nguyen; D R Morel; M Jaconi
Journal:  MAGMA       Date:  2004-12-16       Impact factor: 2.310

Review 3.  The Oxygen Paradox, the French Paradox, and age-related diseases.

Authors:  Joanna M S Davies; Josiane Cillard; Bertrand Friguet; Enrique Cadenas; Jean Cadet; Rachael Cayce; Andrew Fishmann; David Liao; Anne-Laure Bulteau; Frédéric Derbré; Amélie Rébillard; Steven Burstein; Etienne Hirsch; Robert A Kloner; Michael Jakowec; Giselle Petzinger; Delphine Sauce; Florian Sennlaub; Isabelle Limon; Fulvio Ursini; Matilde Maiorino; Christina Economides; Christian J Pike; Pinchas Cohen; Anne Negre Salvayre; Matthew R Halliday; Adam J Lundquist; Nicolaus A Jakowec; Fatima Mechta-Grigoriou; Mathias Mericskay; Jean Mariani; Zhenlin Li; David Huang; Ellsworth Grant; Henry J Forman; Caleb E Finch; Patrick Y Sun; Laura C D Pomatto; Onnik Agbulut; David Warburton; Christian Neri; Mustapha Rouis; Pierre Cillard; Jacqueline Capeau; Jean Rosenbaum; Kelvin J A Davies
Journal:  Geroscience       Date:  2017-12-21       Impact factor: 7.713

Review 4.  Strategies to optimize kidney recovery and preservation in transplantation: specific aspects in pediatric transplantation.

Authors:  Tackwa Khalifeh; Edouard Baulier; Sylvain Le Pape; Thomas Kerforne; Remy Coudroy; Souleymane Maiga; Thierry Hauet; Michel Pinsard; Frederic Favreau
Journal:  Pediatr Nephrol       Date:  2014-09-04       Impact factor: 3.714

5.  Temporal course of microvascular obstruction after myocardial infarction assessed by MRI.

Authors:  Nadine Abanador-Kamper; Vasiliki Karamani; Lars Kamper; Hilmar Brinkmann; Patrick Haage; Melchior Seyfarth
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

6.  Early postmyocardial infarction survival in Murphy Roths Large mice is mediated by attenuated apoptosis and inflammation but depends on genetic background.

Authors:  Darlene L Hunt; Patrick H Campbell; Alexander C Zambon; Karen Vranizan; Sylvia M Evans; Hai-Chien Kuo; Ken D Yamaguchi; Jeffrey H Omens; Andrew D McCulloch
Journal:  Exp Physiol       Date:  2011-10-03       Impact factor: 2.969

Review 7.  A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology.

Authors:  Terence J Coderre; Gary J Bennett
Journal:  Pain Med       Date:  2010-08       Impact factor: 3.750

8.  MRI manifestations of persistent microvascular obstruction and acute left ventricular remodeling in an experimental reperfused myocardial infarction.

Authors:  Yuesong Yang; John J Graham; Kim Connelly; Warren D Foltz; Alexander J Dick; Graham A Wright
Journal:  Quant Imaging Med Surg       Date:  2012-03

9.  Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemia-reperfusion in a rat model.

Authors:  J Grönros; A Kiss; M Palmér; C Jung; D Berkowitz; J Pernow
Journal:  Acta Physiol (Oxf)       Date:  2013-04-15       Impact factor: 6.311

10.  Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs.

Authors:  Bodh I Jugdutt; Arivazhagan Palaniyappan; Richard R E Uwiera; Halliday Idikio
Journal:  Mol Cell Biochem       Date:  2008-11-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.